Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No pharmacokinetic data located for Cardiogen in PubMed/PMC.
No human dosing regimen found. The only quantitative dose data is an in-vitro/organotypic tissue-culture effective concentration of 0.05 ng/mL, which is NOT convertible to a per-administration human dose.
No human clinical study located. Available evidence is a rat sarcoma tumor-modifying study and a rat organotypic heart-tissue-culture study, both Khavinson-lineage. Notably the animal endpoints (tumor apoptosis/necrosis) are not cardiovascular despite the 'cardioprotector' label, underscoring how indirect the evidence is. MW 489.5 Da confirmed for the Ala-Glu-Asp-Arg tetrapeptide (PubChem CID 11583989).
No human safety data exist for Cardiogen. Animal tumor-model data demonstrate biological activity but say nothing about safety in healthy humans. Absence of reported harm is not evidence of safety.
- Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers · journal
- Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats · pubmed
- [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats] · pubmed
- PubChem Compound Summary CID 11583989, H-Ala-Glu-Asp-Arg-OH (MW 489.5) · other